Page URL:

Promising new gene therapy for Duchenne Muscular Dystrophy

25 October 2009
Appeared in BioNews 531

A potential new gene therapy for Duchenne Muscular Dystrophy (DMD) is now set to enter clinical trials after encouraging results in mice. The multinational team of scientists, publishing their findings in the journal Molecular Therapy, demonstrated that the therapy dramatically prevented severe muscle deterioration and extended the lifespan of mice with symptoms of DMD.

DMD is the most prevalent of the nine types of muscular dystrophy and indeed one of the commonest genetic disorders to affect children globally. One in 3500 boys are afflicted with this incurable disease, which results in progressive weakness and wasting of the muscles. Mobility is gradually lost, leaving most affected children wheelchair-bound before their teens, and death typically ensues before 30 years of age.

DMD is caused by a mutation in a gene found on the X chromosome which codes for a protein called dystrophin, an important structural component of muscle. Unlike males, females have 2 copies of the X chromosome and having just one normal copy of the gene is sufficient to produce enough functional protein to compensate. Women may be 'carriers' of the disease however and can pass the disease onto any sons. The new gene therapy works by masking the faulty part of the dystrophin gene. The technique, referred to as 'exon-skipping', results in a shortened but functional dystrophin protein.

Mice lacking both dystrophin and a similar protein called utrophin have a disease which closely resembles DMD. When given once weekly injections of the therapy, the treated mice had improved mobility compared to untreated mice and their limb strength was similar to normal mice. Most of the untreated mice died by 10 weeks of age, but the treated mice still appeared healthy at 26 weeks, when the study ended.

Other gene therapies for DMD, including another one based on 'exon-skipping', are already in human trial and are showing promising initial results. This new therapy however, developed by AVI BioPharma, is additionally tagged with small protein molecules called 'peptide-conjugated morpholino oligomers' (PPMOs) which improve absorption into the muscle tissue. The advantage therein is twofold: the therapy is likely to work in a greater proportion of DMD cases and improvement in symptoms and life expectancy is predicted to be even more pronounced.

'These findings, should they prove to be repeatable in human subjects, hold great promise for the treatment of DMD patients,' said the senior author of the study, Dame Kay Davis of Oxford University. 'It raises the prospect that we can make a pretty spectacular clinical difference'.
Muscular Dystrophy: Exon Skipping Shows Dramatic Effects In Preventing, Treating Muscle-wasting Disease In Mice
ScienceDaily |  21 October 2009
'Spectacular results' hailed for muscular dystrophy drug
The Times |  21 October 2009
7 October 2013 - by Robert Meadowcroft and Neil Bennett 
The families of children and young people with the severe genetic muscle-wasting condition Duchenne muscular dystrophy received a heavy blow last week...
23 September 2013 - by Dr Anna Cauldwell 
A highly anticipated experimental treatment for the genetic condition Duchenne Muscular Dystrophy has failed in a key test of its effectiveness in a critical phase III clinical trial.
9 September 2013 - by James Brooks 
A parliamentary report has recommended a ring-fenced fund to ensure access to 'low volume, high cost' treatments for rare diseases...
1 August 2011 - by Dr Nadeem Shaikh 
UK researchers have successfully trialled a new drug to help patients with a severe form of muscular dystrophy....
13 June 2011 - by Sarah Pritchard 
The NHS must be prepared to screen every newborn baby for Duchenne muscular dystrophy (DMD) – the most severe form of muscular dystrophy – in three years time, says a leading UK geneticist who explains that promising treatments are close to becoming a reality...
15 September 2008 - by Ailsa Stevens 
BioNews reporting from the British Society for Human Genetics (BSHG) annual conference in York:By Ailsa Taylor:A new investigational drug, potentially able to treat up to 2400 different genetic disorders, has been shown to induce production of a vital protein missing in patients with cystic fibrosis, the UK's most...
30 April 2007 - by Heidi Nicholl 
A new drug is being trialled in humans which has been able to cure Duchenne muscular dystrophy (DMD) in mice with symptoms of the disease. The drug, named PTC124, has been developed by scientists working at the University of Massachusetts Medical School and Pennsylvania University Medical School...
30 March 2006 - by BioNews 
US researchers have begun a clinical trial to test a new gene therapy treatment for Duchenne muscular dystrophy (DMD), an inherited muscle-wasting disorder. The team, based at the Columbus Children's Hospital in Ohio, will test the safety and effectiveness of gene injections in six affected boys aged 8-12 years...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.